{"id":"W4379662245","doi":"10.1200/jco.2023.41.17_suppl.lba5506","title":"Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Bevacizumab; Internal medicine; Carboplatin; Taxane; Population; Oncology; Paclitaxel; BRCA mutation; Ovarian cancer; Urology; Cancer; Chemotherapy; Cisplatin; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006020376,0.0005087858,0.000972783,0.0001990998,0.0001816171,0.0006665711,0.000518301,0.0005267351,0.003158286],"category_scores_gemma":[0.0005917738,0.0002864747,0.0007525818,0.0002789526,0.0003090302,0.0004553999,0.0002468231,0.001503254,0.0004095997],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008012418,"about_ca_system_score_gemma":0.0007631217,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001590472,"about_ca_topic_score_gemma":0.006118299,"domain_scores_codex":[0.9997901,0.00009418349,0.00001444039,0.00003650085,0.00001854537,0.00004624139],"domain_scores_gemma":[0.9996935,0.00005329415,0.00008516048,0.00001810363,0.00001056481,0.0001392952],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8608451,0.01036776,0.005420099,0.0008211397,0.001392829,0.00009951484,0.0001021754,0.001046614,0.008584225,0.0002293656,0.002752263,0.1083389],"study_design_scores_gemma":[0.7904913,0.1814017,0.01841836,0.0001269987,0.001169195,0.0003422298,0.00008721764,0.001416562,0.002514351,0.0002592289,0.003750386,0.00002243667],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9915736,0.004455596,0.0002054539,0.0004017435,0.0001391277,0.0005899844,0.0005802343,0.00005505354,0.001999127],"genre_scores_gemma":[0.9946073,0.001973009,0.0004125255,0.0004151675,0.00008089207,0.0004035156,0.0008224131,0.000007819662,0.001277379],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003158286,"threshold_uncertainty_score":0.01056558,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03271190038227768,"score_gpt":0.3935138860739538,"score_spread":0.3608019856916761,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}